StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
12
Publishing Date
2022 - 12 - 27
1
2022 - 07 - 28
1
2022 - 06 - 21
1
2022 - 05 - 09
1
2022 - 04 - 04
1
2021 - 10 - 06
2
2021 - 08 - 09
2
2021 - 06 - 10
1
2021 - 05 - 25
1
2020 - 12 - 22
1
Sector
Health technology
12
N/a
3
Tags
Acer-001
10
Acer-801
7
Acquire
1
Acquisition
2
Alliances
1
Application
7
Approval
1
Biotech
1
Celiprolol
4
Ceo
1
Ces
2
China
1
Clinical-trials-phase-ii
3
Collaboration
4
Commercial
2
Commercialization
4
Conference
7
Designation
2
Disease
6
Drug
8
Earnings
3
Edsivo
2
Enroll
3
Europe
5
Events
2
Expected
2
Fda
12
Fda acceptance
2
Financial
5
Financial results
5
Genetown
11
Granted
2
Growth
2
License
2
Market
2
Meeting
2
Metabolic
4
N/a
46
Nasdaq
3
New drug
4
Patent
7
Pdufa
2
Pharmaceutical
5
Phase 3
2
Presentation
4
Rare
2
Research
3
Resubmission
2
Results
17
Review
2
Submission
4
Syndros
2
Therapeutics
54
Topline
3
Treatment
14
Trial
9
Update
9
Urea
12
Urine
4
Worldwide
2
Entities
22nd century group, inc
10
Abbott laboratories
79
Abbvie inc.
42
Acer therapeutics inc.
12
Adma biologics inc
18
Amgen inc.
23
Amneal pharmaceuticals, inc.
15
Ani pharmaceuticals, inc.
17
Apyx medical corporation
12
Aquestive therapeutics, inc.
15
Ardelyx, inc.
11
Arrival
10
Astellas pharma inc
17
Avenue therapeutics, inc.
10
Becton, dickinson and company
13
Beigene, ltd.
16
Biogen inc.
32
Biomarin pharmaceutical inc.
10
Biontech se
24
Bluebird bio, inc.
13
Boston scientific corporation
11
Brainstorm cell therapeutics inc.
14
Bristol-myers squibb company
20
Coherus biosciences, inc.
23
Eagle pharmaceuticals, inc.
11
Eli lilly and company
71
Eyenovia, inc.
13
Fortress biotech, inc.
14
Gilead sciences, inc.
21
Glaxosmithkline plc
14
Incyte corporation
23
Inhibikase therapeutics, inc.
10
Ionis pharmaceuticals, inc.
13
Jaguar health, inc.
16
Johnson & johnson
227
Medtronic plc
28
Merck & company, inc.
36
Mesoblast limited
15
Moderna, inc.
13
Novartis ag
28
Novavax, inc.
11
Novo nordisk a/s
11
Ocugen, inc.
15
Orange
63
Perrigo company
90
Pfizer, inc.
74
Reata pharmaceuticals, inc.
12
Regeneron pharmaceuticals, inc.
50
Sanofi
236
Seagen inc.
10
Soligenix, inc.
14
Sorrento therapeutics, inc.
21
T2 biosystems, inc.
14
Takeda pharmaceutical company limited
17
Teva pharmaceutical industries ltd
22
Thermo fisher scientific inc
16
Tonix pharmaceuticals holding corp.
12
Verrica pharmaceuticals inc.
13
Vertex pharmaceuticals incorporated
14
Veru inc.
14
Symbols
ACER
12
RLFTF
3
RLFTY
3
Exchanges
Nasdaq
12
Crawled Date
2022 - 12 - 27
1
2022 - 07 - 28
1
2022 - 06 - 21
1
2022 - 05 - 09
1
2022 - 04 - 04
1
2021 - 10 - 06
2
2021 - 08 - 09
2
2021 - 06 - 10
1
2021 - 05 - 25
1
2020 - 12 - 22
1
Crawled Time
07:00
1
13:00
6
14:00
2
15:20
1
16:00
2
Source
www.acertx.com
1
www.biospace.com
7
www.globenewswire.com
4
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Fda
entities :
Acer therapeutics inc.
save search
Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ for Patients with Urea Cycle Disorders
Published:
2022-12-27
(Crawled : 14:00)
- globenewswire.com
RLFTF
|
$1.43
11.45%
3.8K
|
n/a
|
4733.33%
|
O:
3.33%
H:
12.26%
C:
8.06%
RLFTY
|
$1.4006
733.33%
100
|
n/a
|
-78.44%
|
O:
2.37%
H:
0.0%
C:
0.0%
ACER
|
$0.9
-3.61%
420K
|
Health Technology
|
-75.81%
|
O:
-3.23%
H:
0.28%
C:
-31.11%
urea
fda
approval
therapeutics
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDsPrescription Drug User Fee Act (PDUFA) target action date set for January 15, 2023
Published:
2022-07-28
(Crawled : 15:20)
- biospace.com/
RLFTF
|
$1.43
11.45%
3.8K
|
n/a
|
3961.62%
|
O:
3.08%
H:
0.0%
C:
-6.79%
ACER
|
$0.9
-3.61%
420K
|
Health Technology
|
-37.06%
|
O:
0.7%
H:
4.86%
C:
-1.39%
acer-001
treatment
fda
drug
set
resubmission
therapeutics
review
Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application (NDA) for ACER-001
Published:
2022-06-21
(Crawled : 16:00)
- biospace.com/
RLFTF
|
$1.43
11.45%
3.8K
|
n/a
|
4733.33%
|
O:
-21.33%
H:
27.12%
C:
14.41%
RLFTY
|
$1.4006
733.33%
100
|
n/a
|
-68.17%
|
O:
-15.91%
H:
8.65%
C:
8.65%
ACER
|
$0.9
-3.61%
420K
|
Health Technology
|
-48.86%
|
O:
-10.23%
H:
0.0%
C:
0.0%
acer-001
fda
drug
application
therapeutics
review
update
Acer Therapeutics Announces Agreement with FDA on Special Protocol Assessment for its Phase 3 EDSIVO™ (celiprolol) Trial in Vascular Ehlers-Danlos Syndrome PatientsPhase 3 DiSCOVER clinical trial initiation expected by end of Q2 2022
Published:
2022-05-09
(Crawled : 13:00)
- biospace.com/
ACER
|
$0.9
-3.61%
420K
|
Health Technology
|
-57.55%
|
O:
-2.83%
H:
0.97%
C:
-9.22%
fda
expected
trial
therapeutics
phase 3
Acer Therapeutics’ EDSIVO™ (celiprolol) Granted FDA Breakthrough Therapy Designation for Vascular Ehlers-Danlos Syndrome
Published:
2022-04-04
(Crawled : 13:00)
- biospace.com/
ACER
|
$0.9
-3.61%
420K
|
Health Technology
|
-69.18%
|
O:
24.66%
H:
3.57%
C:
-16.48%
fda
granted
therapy
edsivo
celiprolol
grant
designation
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Filing of New Drug Application for ACER-001 to Treat Urea Cycle DisordersFDA sets PDUFA target action date of June 5, 2022
Published:
2021-10-06
(Crawled : 14:00)
- biospace.com/
ACER
|
$0.9
-3.61%
420K
|
Health Technology
|
-63.86%
|
O:
12.45%
H:
8.57%
C:
3.57%
urea
new drug
fda
fda acceptance
pdufa
drug
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Filing of New Drug Application for ACER-001 to Treat Urea Cycle Disorders
Published:
2021-10-06
(Crawled : 13:00)
- acertx.com
ACER
|
$0.9
-3.61%
420K
|
Health Technology
|
-63.86%
|
O:
12.45%
H:
8.57%
C:
3.57%
urea
new drug
fda
fda acceptance
drug
Acer Therapeutics and Relief Therapeutics Announce Submission of a New Drug Application to the U.S. FDA for ACER-001 for Treatment of Urea Cycle Disorders
Published:
2021-08-09
(Crawled : 13:00)
- globenewswire.com
ACER
|
$0.9
-3.61%
420K
|
Health Technology
|
-63.56%
|
O:
2.83%
H:
4.33%
C:
3.54%
urea
new drug
treatment
fda
drug
submission
RELIEF THERAPEUTICS Holdings AG: Acer Therapeutics and Relief Therapeutics Announce Submission of a New Drug Application to the U.S. FDA for ACER-001 for Treatment of Urea Cycle Disorders
Published:
2021-08-09
(Crawled : 07:00)
- biospace.com/
ACER
|
$0.9
-3.61%
420K
|
Health Technology
|
-63.56%
|
O:
2.83%
H:
4.33%
C:
3.54%
urea
new drug
treatment
fda
drug
submission
Acer Therapeutics Plans Clinical Trial for EDSIVO™ (celiprolol) Following Type B FDA Meeting
Published:
2021-06-10
(Crawled : 13:00)
- globenewswire.com
ACER
|
$0.9
-3.61%
420K
|
Health Technology
|
-70.59%
|
O:
-0.33%
H:
2.62%
C:
0.0%
fda
trial
celiprolol
edsivo
Acer Therapeutics Plans NDA Submission for ACER-001 in Q3 2021 Following Pre-NDA Meeting with FDA
Published:
2021-05-25
(Crawled : 13:00)
- globenewswire.com
ACER
|
$0.9
-3.61%
420K
|
Health Technology
|
-68.53%
|
O:
1.05%
H:
1.73%
C:
-5.54%
fda
submission
Acer Therapeutics Announces Full Enrollment of Pivotal Bioequivalence Trial of ACER-001 for Urea Cycle DisordersTopline trial results expected in Q1 2021; targeting a pre-NDA meeting with FDA in Q2 2021
Published:
2020-12-22
(Crawled : 16:00)
- biospace.com/
ACER
|
$0.9
-3.61%
420K
|
Health Technology
|
-66.04%
|
O:
0.38%
H:
0.75%
C:
-3.01%
fda
trial results
results
urea
trial
fda ide
enroll
Gainers vs Losers
67%
33%
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.